Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Repare Therapeutics Inc (RPTX)
NASDAQ:RPTX
Repare Therapeutics (RPTX) Stock Price & Analysis
282 Followers
RPTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.98 - $13.85
Previous Close$3.33
Volume93.21K
Average Volume (3M)250.65K
Market Cap
$141.34M
Enterprise Value-$92.88M
Total Cash (Recent Filing)$237.00M
Total Debt (Recent Filing)$2.78M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 08, 2024EPS Estimate
-$0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding42,445,406
10 Day Avg. Volume140,033
30 Day Avg. Volume250,649
Standard Deviation0.22
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.71
Price to Sales (P/S)2.86
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-4.64
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.41
Forecast
1Y Price Target
$14.67Price Target Upside352.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Repare Therapeutics News
PremiumCompany Announcements
Repare Therapeutics Advances Oncology Trials
PremiumCompany Announcements
Repare Therapeutics Announces Board Changes and FD Disclosure
Bulls Say, Bears Say
Bulls Say
Clinical TrialsInitial Phase 1 MINOTAUR data for lunresertib and FOLFIRI showed anti-tumor activity in heavily pre-treated patients with CCNE1 alterations, regardless of prior irinotecan treatment.
Financial StrengthWith approximately $237 million of cash on the balance sheet, Repare Therapeutics is well-funded with a cash runway into mid-2026.
Safety And EfficacyPromising safety and efficacy data were shown in FOLFIRI and lunresertib versus FOLFIRI and placebo.
Bears Say
Partnership TerminationRepare announced that Roche had made the decision to terminate its collaboration agreement with Repare for camonsertib.
Program ShutdownsMultiple other programs were shuttered by Roche around the camonsertib announcement.
Stock PerformanceLosing Roche as a partner for camonsertib resulted in RPTX stock dropping 64% to where it now trades at about half of proforma cash.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RPTX FAQ
What was Repare Therapeutics Inc’s price range in the past 12 months?
Repare Therapeutics Inc lowest stock price was $2.98 and its highest was $13.85 in the past 12 months.
What is Repare Therapeutics Inc’s market cap?
Currently, no data Available
When is Repare Therapeutics Inc’s upcoming earnings report date?
Repare Therapeutics Inc’s upcoming earnings report date is Aug 08, 2024 which is in 36 days.
How were Repare Therapeutics Inc’s earnings last quarter?
Repare Therapeutics Inc released its earnings results on May 07, 2024. The company reported $0.3 earnings per share for the quarter, beating the consensus estimate of $0.016 by $0.284.
Is Repare Therapeutics Inc overvalued?
According to Wall Street analysts Repare Therapeutics Inc’s price is currently Undervalued.
Does Repare Therapeutics Inc pay dividends?
Repare Therapeutics Inc does not currently pay dividends.
What is Repare Therapeutics Inc’s EPS estimate?
Repare Therapeutics Inc’s EPS estimate is -$0.87.
How many shares outstanding does Repare Therapeutics Inc have?
Repare Therapeutics Inc has 42,445,408 shares outstanding.
What happened to Repare Therapeutics Inc’s price movement after its last earnings report?
Repare Therapeutics Inc reported an EPS of $0.3 in its last earnings report, beating expectations of $0.016. Following the earnings report the stock price went up 15.549%.
Which hedge fund is a major shareholder of Repare Therapeutics Inc?
Among the largest hedge funds holding Repare Therapeutics Inc’s share is ARK Investment Management LLC. It holds Repare Therapeutics Inc’s shares valued at 13M.
---
Repare Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.67 (352.78% Upside)
$14.67 (352.78% Upside)
Blogger Sentiment
Bullish
RPTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 116.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.52%
12-Months-Change
Fundamentals
Return on Equity
-18.91%
Trailing 12-Months
Asset Growth
-21.77%
Trailing 12-Months
Company Description
Repare Therapeutics Inc
Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
---
RPTX Stock 12 Month Forecast
Average Price Target
$14.67
▲(352.78% Upside)
Technical Analysis
Best Analysts Covering RPTX
1 Year
1 Year Success Rate
1/13 ratings generated profit
1 Year Average Return
-35.94%
assigned a buy rating 22 days ago
Copying Tim Chiang's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -35.94% per trade.
---